Αρχική World News No improvement in OS, but more grade 3 or higher AEs with... World News No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC Από Ogkologos - 24 Σεπτεμβρίου, 2026 90 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG/NRG S1914 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Longtime NPR Reporter Shares Diagnosis to Bring More Awareness to Metastatic... 26 Ιουνίου, 2021 Adjuvant Pembrolizumab Improves QoL in Patients with High-Risk Resected Melanoma 29 Νοεμβρίου, 2022 Coronavirus reports – Part 10: “I didn’t see my mum before... 15 Σεπτεμβρίου, 2021 EMA Recommends Extension of Indications for Ibrutinib 11 Σεπτεμβρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated... Addressing Mental Health Needs of Adolescent and Young Adult Cancer Survivors FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma French Senate Committee Backs ESMO Call to Revise EU Regulation to...
